The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and
bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic
patients with albuminuria despite recommended antihypertensive treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Steno Diabetes Center Steno Diabetes Center Copenhagen